Marrone Bio Innovations Inc (MBII) Jumps 5.16% on February 10

Equities Staff |

Marrone Bio Innovations Inc (MBII) was among the biggest gainers on the Russell 2000 for Wednesday February 10 as the stock popped 5.16% to $0.98, representing a gain of $0.048 per share. Some 3,854 shares traded hands on 17 trades, compared with an average daily volume of 38,520 shares out of a total float of 24.46 million. The stock opened at $0.96 and traded with an intraday range of $0.98 to $0.92.

After today's gains, Marrone Bio Innovations Inc reached a market cap of $23.93 million. Marrone Bio Innovations Inc has had a trading range between $4.43 and $0.62 over the last year, and it had a 50-day SMA of $1.14 and a 200-day SMA of $1.99.

Marrone Bio Innovations Inc is a producer of bio-based pest management and plant health products. The Company offers its products to the markets that use conventional chemical pesticides, including certain agricultural and water markets.

Marrone Bio Innovations Inc is based out of Davis, CA and has some 86 employees. Its CEO is Pamela G. Marrone.

For a complete fundamental analysis analysis of Marrone Bio Innovations Inc, check out’s Stock Valuation Analysis report for MBII. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


A peer-to-Peer authentic photo marketplace disrupting the $10B commercial photography industry.

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…